Importance of programmed death ligands in vitiligo

Not Applicable

Conditions: Health Condition 1: L80- Vitiligo

Registration Number: CTRI/2020/04/024735

Lead Sponsor: Pigmentary Disorders Society India

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

Consecutive patients with clinical diagnosis of vitiligo vulgaris; and age > 18 years and <60 years will be recruited in this study.

The study shall include 40 consecutive patients having vitiligo (20 stable, 20 active) attending the Pigmentary Clinic of the Department of Dermatology, Venereology and Leprology at Postgraduate Institute of Medical Education and Research, Chandigarh.

Controls: Ten healthy individuals (accompanying the patients and having no skin/ systemic disease) will be taken as controls.

Exclusion Criteria

Leucoderma secondary to other causes

Pregnancy/Lactation

Patients with severe hepatic, renal, thyroid or other systemic disorder

Pre-existing malignancy

Any other skin disease

Patients receiving topical or systemic therapy of any form for vitiligo in past 6 weeks.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess the blood levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand-1 (sPD-L1) in patients having vitiligo through ELISA.Timepoint: To assess the blood levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand-1 (sPD-L1) in patients having vitiligo through ELISA at the time of recruitment.

Secondary Outcome Measures

Name	Time	Method
1.To correlate the blood levels of sPD-1 and sPD-L1 with disease activity and severity (stable vs active; among different vitiligo disease activity [VIDA], and vitiligo area scoring index [VASI] scores). <br/ ><br>2.To correlate the blood levels of sPD-1 and sPD-L1 with those of interleukins [IL]-2, 7 and 15; and interferon gamma (IFN-ï?§); which shall be measured through ELISA. <br/ ><br>Timepoint: cross-sectional